Commentary: Anatomical constitution of sense organs as a marker of mental disorders by Thomas Schwitzer et al.
GENERAL COMMENTARY
published: 24 March 2016
doi: 10.3389/fnbeh.2016.00056
Frontiers in Behavioral Neuroscience | www.frontiersin.org 1 March 2016 | Volume 10 | Article 56
Edited by:
Ahmed A. Moustafa,







Received: 23 December 2015
Accepted: 08 March 2016
Published: 24 March 2016
Citation:
Schwitzer T, Schwan R, Bernardin F,
Jeantet C, Angioi-Duprez K and
Laprevote V (2016) Commentary:
Anatomical constitution of sense
organs as a marker of mental
disorders.
Front. Behav. Neurosci. 10:56.
doi: 10.3389/fnbeh.2016.00056
Commentary: Anatomical
constitution of sense organs as a
marker of mental disorders
Thomas Schwitzer 1, 2, 3*, Raymund Schwan 1, 2, 4, Florent Bernardin 1, 2, Coline Jeantet 5,
Karine Angioi-Duprez 6 and Vincent Laprevote 1, 2, 4
1 Pôle Hospitalo-Universitaire de Psychiatrie, Centre Psychothérapique de Nancy, Laxou, France, 2 EA7298, INGRES,
Université de Lorraine, Nancy, France, 3 Institut National de la Santé et de la Recherche Médicale U1114, Fédération de
Médecine Translationnelle de Strasbourg, Département de Psychiatrie, Centre Hospitalier Régional Universitaire de
Strasbourg, Strasbourg, France, 4Maison des Addictions, CHU Nancy, Nancy, France, 5 EA4432, InterPsy, Université de
Lorraine, Nancy, France, 6 Service d’Ophtalmologie, CHU Nancy, Nancy, France
Keywords: schizophrenia, retina, pattern electroretinogram, pathophysiology, dopamine
A Commentary on
Anatomical constitution of sense organs as a marker of mental disorders
by Güell, F., and Bernácer, J. (2015). Front. Behav. Neurosci. 9:59. doi: 10.3389/fnbeh.2015.00059
Research in neuroscience and psychiatry is limited by the difficulty to accurately access brain
functioning. There is currently a need to develop new methods assessing the neurobiological
underpinning of brain dysfunctions (London et al., 2013; Lavoie et al., 2014; Güell and Bernácer,
2015; Laprevote et al., 2015; Schwitzer et al., 2015a,b). On this basis, Güell and Bernácer in
an exciting article recently discussed the relevance of studying visual perception in mental
disorders and especially in schizophrenia (Güell and Bernácer, 2015). Among other deficits, they
outlined retinal functional and anatomical deficits detected in schizophrenia using respectively
flash electroretinogram (fERG) and optical coherence tomography (OCT). However, we would
like to suggest herein that the pattern electroretinogram (PERG), a retinal functional recording,
might provide a relevant complementary measurement to enhance understanding of biological
mechanisms underlying brain disorders in schizophrenia.
Flash and pattern ERG allow for the assessment of specific cell types of the neural retina and give
different information on the pathophysiology. Using a light stimulation, the fERG mainly assesses
the electric biopotential evoked by the first stages of visual processing namely photoreceptors
and bipolar-Müller cell complex (Holder et al., 2010). As previously found, these first stages are
altered in schizophrenia (Warner et al., 1999; Balogh et al., 2008; Hébert et al., 2015). However,
the fERG does not significantly provide information concerning the ganglion cells, the axons
of which form the optic nerve. The ganglion cells constitute the ultimate retinal relay before
the transmission of the visual information from the retina to the visual cortex. The functional
properties of these cells can be assessed by the PERG using the central presentation of reversing
black and white checkerboards (Bach et al., 2013). The On-Off organization of the ganglion cells
receptive fields makes these cells particularly sensitive to the alternate changes in contrast levels
of the checkerboards, and leads to large responses in the PERG (Holder et al., 2010). The electrical
signal transmitted to ganglion cells originates from photoreceptor and bipolar cells and is under the
influence of interneurons cells (amacrine and horizontal cells). The signal elicited at the ganglion
cell level thus results from the integration of several retinal stages. Since it is more integrated there
than at the photoreceptor and bipolar cell level we suggest that its measurement might be a useful
complementary test to approach the neural function in schizophrenia. Furthermore, the layer of
the ganglion cells is the first retinal stage providing information in the form of action potentials.
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Trustworthy evidence underlines that PERG protocols are
good candidates to investigate dopamine transmission, a
neurotransmitter known to be involved in schizophrenia. Indeed,
the manipulation of the contrast level of the reversing black and
white checkerboards during PERG informs on retinal contrast
processing, which is largely influenced by retinal dopaminergic
amacrine cells (Djamgoz et al., 1997). Moreover, alterations
of retinal contrast processing detected with reversal PERG
stimulation were found in Parkinson’s disease, a dopaminergic
pathology (Garcia-Martin et al., 2014). Importantly, these
changes appear to be good biological markers, inasmuch as they
predict quality of life and disease severity in Parkinson’s disease.
PERG shares several advantages with fERG. Measurements
of PERG are non-invasive, relatively fast, easy-to-use, and
inexpensive. Importantly, PERG also has some additional
advantages relative to fERG. Unlike most protocols of fERG,
there is no need to dilate the pupil, making the PERG less
invasive than fERG, with no alteration of visual perception.
Second, whereas the fERG is evaluated after adaptation
periods in darkness and light, the PERG is entirely measured
in light conditions without any adaptation period (Bach
et al., 2013; McCulloch et al., 2015). These methodological
advantages may facilitate the use of PERG in patients with
schizophrenia. As the PERG contrast processing appears sensitive
to dopaminergic dysfunction, it might represent a suitable
approach for monitoring anti-psychotic response, an important
part of patient care. Finally, the PERG can be coupled with
other retinal measurements such as the fERG to provide
a more thorough picture of the pathophysiology of the
disease.
As previously described, measures of PERG assess the
functional properties of the retinal ganglion cells, the axons
of which form the optic nerve. Anatomical constitution and
organization of these cells can be evaluated by retinal imaging
techniques, namelyOCT. Several studies found retinal nerve fiber
layer (RNFL) thinning in schizophrenia, which was observed
with spectral domain OCT (Chu et al., 2012; Lee et al., 2013;
Silverstein et al., 2015). RNFL is constituted by the fibers of
the optic nerve and its thinning is a direct reflection of a loss
of ganglion cell axons. We suppose that anatomical alterations
of retinal ganglion cells observed in schizophrenia could lead
to functional deficits of these cells. Such impairments could be
detected by PERG. Importantly, adding functionalmeasurements
like PERG to imaging techniques such as OCT may provide a
potential structure-function correlation.
Although PERG might appear as a relevant measure to
indirectly approach the pathophysiology of schizophrenia, there
are several limitations and a large number of steps required
to demonstrate the usefulness of this exam in the better
understanding of the disease. To this date, PERG measurements
have not been evaluated in schizophrenia patients yet and
consequently there is no certainty that differences between
patients and healthy controls would be observed. Accordingly,
case-control studies with a large number of subjects and
standardized protocols are needed to eventually demonstrate
differences between patients and controls. This constitutes the
starting point to investigate the relevance of this method.
Additionally, the pathophysiology of schizophrenia remains
to this date elusive and involves more complex mechanisms
than only dopaminergic dysfunctions (Khandaker et al., 2015).
As a consequence, only one exam such as PERG does not
alone give sufficient information on central dysfunctions but
should be coupled with other assessments to provide a clearer
picture of the disease. Then, in the case where differences
between groups would be observed, control groups of patients
with other dopaminergic pathologies are crucial to conclude
on the specificity of PERG. Also, as we can consider that it
is impossible to have medication-free schizophrenia patients,
the effects of different types of psychotropic drugs such as
antipsychoticsmust be tested on PERG recordings to differentiate
the potential effects of medications or disease. Finally, although
there is currently an increasing interest for PERG assessments
in psychiatric research (Schwitzer et al., 2015a, 2016), the
precise mechanisms underlying PERG anomalies should be
investigated to understand the biological underpinning of brain
dysfunctions.
Approximately 0.5% of the population suffers from
schizophrenia, which has psychiatric and cognitive
consequences. A current challenge in neuroscience research is
to develop reproducible measures providing an indirect access
to the brain functioning. In the case of schizophrenia, there is
an urgent need for biological markers enabling early detection
of the disease. Eventually, the PERG might be used as a useful
complementary measurement to allow a better understanding of
the pathophysiology of schizophrenia.
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